Associated Papers
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W et al.
Journal of Virology, 2002
Transmission of antiretroviral-drug-resistant HIV-1 variants.
Yerly S et al.
Lancet (london, England), 1999
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.
Molla A et al.
Virology, 1998
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.
Schock HB et al.
The Journal of Biological Chemistry, 1996
Select a paper to view details